Rainbow Childrens Medicare Limited (RAINBOW)

Healthcare · Healthcare Services · NSE · Updated 15 July 2026

₹1,484.1 ↓ 2.78% (1Y)

🎯 Key Takeaways

Rainbow Children's Medicare is in a high-growth, capital-intensive expansion phase within pediatric and maternal healthcare, leveraging its asset-light hub-and-spoke model to scale profitably across urban and emerging tier-II markets. Management is executing a clear strategy of organic expansion with targeted acquisitions, supported by strong cash generation and zero debt, positioning the company for sustained margin improvement and market leadership despite near-term capital outlays.
⚠️ High capital intensity required for bed expansion could pressure near-term cash flows if occupancy targets are not met.

Market Cap

₹13,570

P/E Ratio

52.2

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About RAINBOW 📊 Interactive Charts

📖 The Story

Rainbow Children's Medicare is in a high-growth, capital-intensive expansion phase within pediatric and maternal healthcare, leveraging its asset-light hub-and-spoke model to scale profitably across urban and emerging tier-II markets. Management is executing a clear strategy of organic expansion with targeted acquisitions, supported by strong cash generation and zero debt, positioning the company for sustained margin improvement and market leadership despite near-term capital outlays.

📰 What's Happening

In Q4 FY26, the company reported 24% YoY revenue growth to ₹459.9 crores and 38% YoY PAT growth to ₹78.2 crores, driven by robust performance in pediatric and maternal care. Management highlighted progress toward a 60% occupancy target in mature hospitals, with new 100-bed facilities planned in Coimbatore and Gurgaon Sector 56 slated for H2 FY28 operations. Capex of ₹61 crores in Q4 supported expansion, including ₹400 crores allocated to Gurugram and ₹300–350 crores for other new beds. IVF revenue grew ~25% YoY and now contributes ~3.7% of total revenue. The firm emphasized scalability through digital transformation, including new CRM and HIS platforms, and plans to fund its 900-bed pipeline via internal accruals.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Q3FY25
Revenue	398
Operating Profit	148
OPM %	33.8%
Net Profit	69
EPS	₹6.76

Revenue growth accelerated to 24% YoY in Q4 FY26 from 12% YoY in FY26, while PAT growth outpaced revenue at 38% YoY, indicating operating leverage. The company maintained strong profitability with OPM of 33.8% in Q3FY25 and sustained cash generation, ending with ₹594 crores in liquidity and no debt. Capex of ₹217 crores annually is being deployed toward adding 500 beds and expanding the pipeline, with a focus on high-margin pediatric super-specialties. The margin expansion and profit growth outpacing revenue suggest improving operational efficiency amid scale.

🔮 Management Outlook & What's Next

Management targets 60% occupancy in mature hospitals and plans to add 2,500 beds over five years at a capital investment of ₹2,200 crores, including ₹45 crores annually for maintenance, ₹400 crores for Gurugram, and ₹300–350 crores for other new beds. IVF revenue is expected to grow ~25% YoY over the next three years, contributing to diversification. New 100-bed hospitals in Coimbatore and Gurgaon Sector 56 are scheduled for H2 FY28 operations, with additional expansions in Bangalore, Chennai, Warangal, and Guwahati. Digital transformation initiatives, including CRM and HIS platforms, are underway to support scalable operations.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Healthcare Services

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Apollo Hospitals Enterprise Limited	1.16 L Cr	64.5	20.5%	21.9%	0.64
Max Healthcare Institute Limited	1.02 L Cr	101.2	—	—	—
Fortis Healthcare Limited	72,752	94.6	—	—	—
Aster DM Healthcare Limited	39,048	7.1	—	—	—
Narayana Hrudayalaya Ltd.	37,625	47.7	—	—	—
Global Health Limited	33,405	65.8	—	—	—
Krishna Institute of Medical Sciences Limited	30,477	80.3	—	—	—
Dr. Lal Path Labs Ltd.	26,871	63.6	—	—	—
Syngene International Limited	18,295	36.3	—	—	—
Dr. Agarwal's Health Care Limited	14,266	88.8	14.9%	6.8%	0.13

🔗 Peer Stock Analyses

APOLLOHOSP MAXHEALTH FORTIS ASTERDM NH

⚠️ Risk Factors

1. High capital intensity required for bed expansion could pressure near-term cash flows if occupancy targets are not met. 2. Execution risk in scaling new hospitals in tier-II cities and integrating acquired facilities like Prashanthi and Pratiksha Hospitals. 3. Competitive pressures in pediatric and IVF segments may affect pricing and margin trajectory. 4. Regulatory or operational risks in healthcare delivery, including compliance and quality control across an expanding network.

📋 Recent Filings

🧠 Analyst's Read

Rainbow Children's Medicare is executing a scalable growth strategy in pediatric and maternal healthcare with strong cash generation and no debt, but its future performance hinges on successful execution of expansion plans and achieving occupancy targets. Investors should monitor capex discipline, bed utilization rates, and IVF revenue growth as key near-term indicators.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on RAINBOW

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-15.

📡 Get AI alerts when RAINBOW files new disclosures

Track RAINBOW filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track RAINBOW — Free

Free account · 2 AI queries/day